Pura Vida Investments, LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 12, 2025), Pura Vida Investments, LLC reported 8 stock positions worth $16.4 million. Its top holding was Beta Bionics (BBNX) at 34.0% of the portfolio, followed by Insight Molecular Diagnostic (IMDX, 19.2%) and Caris Life Sciences (CAI, 16.6%). Compared with Q2 2025, it added to 3 and reduced 4. The biggest buy was Caris Life Sciences (CAI, shares +100%) and the biggest sale Outset Medical (OM, shares −99%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001590144
- Portfolio Value
- $16.4M (Q3 2025)
- SEC Filing
- 0001590144-25-000009 ↗ filed Nov 12, 2025
Holdings Value
Holdings 8 stocks · $16.4M
| BBNX Beta Bionics Inc. | 34.05% | 281,250 | $5.6M | Add +11150.0% |
| IMDX Insight Molecular Diagnostic | 19.16% | 947,134 | $3.1M | Add +4964.9% |
| CAI Caris Life Sciences Inc. | 16.58% | 89,940 | $2.7M | Add +99.9% |
| ESTA Establishment Labs Holdings | 11.24% | 45,000 | $1.8M | Reduce -50.0% |
| NSPR Inspiremd Inc. | 6.62% | 450,517 | $1.1M | No change |
| OM Outset Medical Inc. | 6.09% | 5,000 | $1.0M | Reduce -98.8% |
| MGX Metagenomi Therapeutics Inc. | 3.82% | 264,391 | $627K | Reduce -72.2% |
| NTRA Natera Inc. | 2.45% | 2,500 | $402K | Reduce -99.0% |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 19 | $37.0M | ALMR, BBNX, ESTA, IMDX, NVDA |
| Q1 2026 | 17 | $14.9M | IMDX, BBNX, ESTA, CAI, NSPR |
| Q4 2025 | 18 | $26.8M | BBNX, IMDX, ESTA, CAI, NSPR |
| Q3 2025 | 8 | $16.4M | BBNX, IMDX, CAI, ESTA, NSPR |
| Q2 2025 | 8 | $16.6M | BBNX, IMDX, CAI, ESTA, OM |
| Q1 2025 | 8 | $13.7M | BBNX, IMDX, ESTA, NSPR, KMTS |
| Q4 2024 | 9 | $18.1M | ESTA, MSOS, LUNG, QTRX, IMDX |
| Q3 2024 | 16 | $60.8M | MSOS, ESTA, GKOS, NTRA, ISRG |
| Q2 2024 | 25 | $82.7M | ESTA, GKOS, ISRG, NTRA, MSOS |
| Q1 2024 | 30 | $146.8M | EXAS, ESTA, ISRG, QTRX, LYRA |